XTNT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
23.0M
+10.3%
20.9M
-35.5%
32.4M
-2.7%
33.3M
-6.1%
35.4M
Cost of Revenue
9.7M
+8.8%
8.9M
-39.0%
14.6M
+29.7%
11.3M
+1.2%
11.1M
Gross Profit
13.3M
+11.4%
12.0M
-32.6%
17.8M
-19.3%
22.0M
-9.4%
24.3M
Operating Expenses
22.5M
+51.1%
14.9M
-20.3%
18.7M
-3.9%
19.5M
-1.1%
19.7M
R&D
695.0K
+59.8%
435.0K
-5.2%
459.0K
-27.6%
634.0K
+12.0%
566.0K
SG&A
16.8M
+16.2%
14.5M
-20.7%
18.2M
-3.1%
18.8M
-1.5%
19.1M
Operating Income
-9169000
-213.7%
-2923000
-209.6%
-944000
-137.2%
2.5M
-45.0%
4.6M
EBITDA
-3661000
-53.2%
-2389000
-373.0%
875.0K
-76.4%
3.7M
-36.1%
5.8M
Net Income
-9413000
-204.7%
-3089000
-5519.3%
57.0K
-95.6%
1.3M
-63.2%
3.5M
EPS (Basic)
$-0.07
-250.0%
$-0.02
$0.00
-100.0%
$0.01
-66.7%
$0.03
EPS (Diluted)
$-0.07
-250.0%
$-0.02
$0.00
-100.0%
$0.01
-50.0%
$0.02
Shares (Diluted)
140.3M
+0.1%
140.1M
-11.3%
157.9M
+5.0%
150.4M
+1.2%
148.6M
Xtant Medical (XTNT) โ€” Financials